Monte Rosa Therapeutics (NASDAQ:GLUE) Releases Earnings Results, Misses Expectations By $0.06 EPS

Monte Rosa Therapeutics (NASDAQ:GLUE) released its earnings results on Thursday. The company reported ($0.45) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.39) by ($0.06), FiscalAI reports. The company had revenue of $4.21 million during the quarter, compared to analyst estimates of $10.95 million. Monte Rosa Therapeutics had a negative net margin of 302.69% and a negative return on equity of 52.22%.

Monte Rosa Therapeutics Price Performance

NASDAQ GLUE traded down $0.42 during trading on Friday, reaching $19.39. 547,092 shares of the company’s stock were exchanged, compared to its average volume of 819,558. The business has a 50 day moving average price of $17.69 and a 200-day moving average price of $17.40. The stock has a market capitalization of $1.64 billion, a P/E ratio of -13.10 and a beta of 1.62. Monte Rosa Therapeutics has a fifty-two week low of $3.51 and a fifty-two week high of $25.77.

Wall Street Analysts Forecast Growth

A number of analysts recently issued reports on GLUE shares. Wells Fargo & Company lowered their target price on Monte Rosa Therapeutics from $30.00 to $29.00 and set an “overweight” rating on the stock in a research report on Wednesday, March 18th. Guggenheim cut their price objective on Monte Rosa Therapeutics from $34.00 to $30.00 and set a “buy” rating for the company in a report on Wednesday, March 18th. Wall Street Zen downgraded Monte Rosa Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, March 21st. Zacks Research downgraded shares of Monte Rosa Therapeutics from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, February 4th. Finally, Piper Sandler restated an “overweight” rating and set a $37.00 price objective (up from $27.50) on shares of Monte Rosa Therapeutics in a research note on Wednesday, January 14th. Six equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, Monte Rosa Therapeutics presently has an average rating of “Moderate Buy” and an average target price of $32.80.

Insiders Place Their Bets

In other Monte Rosa Therapeutics news, CEO Markus Warmuth sold 5,466 shares of the business’s stock in a transaction that occurred on Monday, March 2nd. The stock was sold at an average price of $17.92, for a total transaction of $97,950.72. Following the transaction, the chief executive officer owned 613,471 shares of the company’s stock, valued at $10,993,400.32. The trade was a 0.88% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Philip Nickson sold 5,845 shares of the business’s stock in a transaction that occurred on Thursday, April 9th. The stock was sold at an average price of $17.69, for a total value of $103,398.05. Following the transaction, the insider directly owned 55,000 shares in the company, valued at approximately $972,950. This trade represents a 9.61% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold a total of 37,150 shares of company stock valued at $668,694 over the last 90 days. 6.90% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Monte Rosa Therapeutics

A number of institutional investors have recently bought and sold shares of the business. Price T Rowe Associates Inc. MD boosted its holdings in shares of Monte Rosa Therapeutics by 10.4% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 5,118,904 shares of the company’s stock worth $80,265,000 after acquiring an additional 481,844 shares during the period. State Street Corp boosted its holdings in shares of Monte Rosa Therapeutics by 148.9% during the fourth quarter. State Street Corp now owns 2,107,480 shares of the company’s stock worth $33,045,000 after acquiring an additional 1,260,707 shares during the period. AQR Capital Management LLC boosted its holdings in shares of Monte Rosa Therapeutics by 459.4% during the second quarter. AQR Capital Management LLC now owns 1,283,942 shares of the company’s stock worth $5,791,000 after acquiring an additional 1,054,406 shares during the period. Geode Capital Management LLC boosted its holdings in shares of Monte Rosa Therapeutics by 4.6% during the fourth quarter. Geode Capital Management LLC now owns 1,204,844 shares of the company’s stock worth $18,896,000 after acquiring an additional 53,278 shares during the period. Finally, MPM Bioimpact LLC bought a new stake in shares of Monte Rosa Therapeutics during the fourth quarter worth approximately $18,399,000. Institutional investors and hedge funds own 79.96% of the company’s stock.

About Monte Rosa Therapeutics

Monte Rosa Therapeutics is a biotechnology company focused on accelerating drug discovery through the integration of single-cell genomics and artificial intelligence. Founded in 2020 and headquartered in Cambridge, Massachusetts, the company has built a proprietary platform designed to identify novel therapeutic targets and optimize lead candidates for areas of high unmet medical need. By combining cutting-edge computational methods with comprehensive cellular profiling, Monte Rosa aims to streamline the preclinical development process and uncover insights into disease biology that might otherwise remain hidden.

The company’s main business activities center on using its AI-driven discovery engine to pursue programs in immuno-oncology and neuroscience.